Androgel Is FTC's Best Shot At High Court Pay-For-Delay Case
By Melissa Lipman ( July 19, 2012, 9:44 PM EDT) -- The Eleventh Circuit's refusal Wednesday to rehear the Federal Trade Commission's case against settlements Solvay Pharmaceutical Inc. made with generic Androgel makers — just two days after the Third Circuit created a clear appellate split on the issue — has given the agency its best shot at having the U.S. Supreme Court take up its decadelong campaign against pay-for-delay deals....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.